NCT07126301 Aromatherapy Essential Oils to Manage Anxiety and Nausea in Cancer Patients Receiving Infusion in the Ambulatory Setting
| NCT ID | NCT07126301 |
| Status | Recruiting |
| Phase | — |
| Sponsor | City of Hope Medical Center |
| Condition | Hematopoietic and Lymphatic System Neoplasm |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-07-08 |
| Primary Completion | 2027-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2025-07-08 with a primary completion date of 2027-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This clinical trial tests how well aromatherapy essential oils work to manage anxiety and nausea in cancer patients receiving infusions in the ambulatory setting. Current drugs that are given for nausea may cause constipation and fatigue. Therefore, there is interest in exploring complementary therapies, like aromatherapy, that do not carry the same side effects. Using aromatherapy essential oils such as ginger, peppermint, and lavender, may help reduce nausea and anxiety. Some studies have shown significant reductions in nausea and anxiety among cancer patients using these oils, while other studies have had mixed results. Ginger and peppermint oils, in particular, have been associated with helping reduce nausea during chemotherapy, while lavender has shown potential benefits for anxiety. Jojoba oil will be used as a placebo for this research study. Jojoba oil is extracted from the seeds of a jojoba plant, which is a green shrub that is found in the southwestern United States). Jojoba oil is an oil which has no color or smell. Aromatherapy essential oils used through a personal inhalation device during chemotherapy may better manage anxiety and nausea in cancer patients receiving infusions in the ambulatory setting.
Eligibility Criteria
Inclusion Criteria: * Patients must have the ability to understand and sign a written informed consent document, and be willing to follow protocol requirements * Ability to read and understand English for patient reported outcomes * Age \>= 18 years * Eastern Cooperative Oncology Group (ECOG) performance status =\< 2 * Willingness to comply with all study interventions of essential oil aromatherapy * Have been on a moderate- to high-risk emetogenic chemotherapy regimen as defined by the National Comprehensive Cancer Network (NCCN) for at least 1 cycle of therapy * At least 2 remaining infusion appointments on a moderate- to high-risk emetogenic chemotherapy regimen as defined by the NCCN * Have nausea defined as \> 3/10 with last chemotherapy infusion based on screening symptom questionnaire * The study is open to all participants regardless of gender, race, or ethnicity Exclusion Criteria: * Self-reported aversion or sensitivity to lavender oil, peppermint oil, ginger oil, jojoba oil * Uncontrolled respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD) * Mental incapacitation (ex. stroke, brain metastasis etc.) that would cause inability to follow directions, in the opinion of the investigators * Ongoing uncontrolled active psychiatric condition that would interfere in the conduct of the study (e.g., mood disorders, anxiety, psychosis disorders, or substance use) * Self-reported abnormal smelling abilities (for ex: ongoing sinus infections, long covid, etc.) * Aromatherapy use in the last 30 days
Contact & Investigator
Richard T Lee
PRINCIPAL INVESTIGATOR
City of Hope Medical Center
Frequently Asked Questions
Who can join the NCT07126301 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hematopoietic and Lymphatic System Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07126301 currently recruiting?
Yes, NCT07126301 is actively recruiting participants. Visit ClinicalTrials.gov or contact City of Hope Medical Center to inquire about joining.
Where is the NCT07126301 trial being conducted?
This trial is being conducted at Duarte, United States, Irvine, United States.
Who is sponsoring the NCT07126301 clinical trial?
NCT07126301 is sponsored by City of Hope Medical Center. The principal investigator is Richard T Lee at City of Hope Medical Center. The trial plans to enroll 60 participants.